Plunkett Research Online: Diamedica, Inc.

DIAMEDICA, INC. (DMA:TSX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

DiaMedica is a biopharmaceutical company focused on developing novel therapeutic products that will dramatically improve the lives of people with Type 1 diabetes, Type 2 diabetes and other large unmet diseases......



Diamedica, Inc.
Ticker: DMA
Exchange: TSX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 204 477-7590
Fax: 204 453-3745
Address: Two Carlson Parkway
Suite 165
Minneapolis, MN 55447 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
ContactsDescription
Rick PaulsCEO/Director
David GurveyCFO/Vice President, Divisional
See More
DiaMedica is a biopharmaceutical company focused on developing novel therapeutic products that will dramatically improve the lives of people with Type 1 diabetes, Type 2 diabetes and other large unmet diseases......See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201620152014201320122011
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: